P&G, J&J cut sanitary napkin prices by 2-3%

Mumbai: Leading sanitary napkin makers Procter & Gamble (P&G) and Johnson & Johnson (J&J) on Friday passed on to consumers the benefits of the GST exemption on feminine hygiene products. The price reduction is said to be in the range of 2-3% across stock keeping units (SKUs), which is the benefit these companies received after offsetting input tax credit, said industry sources.

The GST exemption came into effect on Friday (July 27). Although the exact price reduction on SKUs is not known, a J&J spokesperson confirmed that the company has rolled out price cuts on sanitary napkins.

A P&G spokesperson said, “As a responsible corporate, P&G is committed to passing the net help of GST rate reduction to customers. We have updated our systems and are passing net benefits to the trade starting today. We have also expedited processes for MRP (maximum retail price) reduction on packs, which will start hitting stores in a few weeks.”

P&G said it is communicating the price reduction to all its trade partners, modern retail partners and distributors. “We will also communicate the price reduction via advertising in mass media to help increase awareness among consumers, shoppers and retailers,” the spokesperson said.

In its Friday (July 27) edition, TOI had reported that in the absence of input tax credit, the extent of price reductions on sanitary napkins would be much lower (up to 2.5%) than what was anticipated (12%).

Industry experts said it can take anywhere between three and five months for a new MRP to take effect in the market across the supply chain. When accelerated, the process can be accomplished in a few weeks. The Rs 4,500-crore sanitary protection market is under-penetrated in India, creating huge room for growth.

  • Related Posts

    KGMU prof suspended for forcing patients to buy meds from pvt store

    Lucknow: Faculty member in the ophthalmology department of KGMU, Prof Sanjiv Gupta, was suspended on charges of prescribing medicines and lenses for cataract surgery that were available at a private…

    CDSCO receives 1,387 adverse drug reaction reports in nine months of 2025

    New Delhi: The pharmacovigilance division of the Central drug regulator has received a total of 1,387 adverse reports, with the highest regarding fixed dose combinations (FDCs), and a total of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    KGMU prof suspended for forcing patients to buy meds from pvt store

    KGMU prof suspended for forcing patients to buy meds from pvt store

    World Record in Robotic Tele-Surgery takes Intercontinental Leap of 20,000 Km

    World Record in Robotic Tele-Surgery takes Intercontinental Leap of 20,000 Km

    CDSCO receives 1,387 adverse drug reaction reports in nine months of 2025

    CDSCO receives 1,387 adverse drug reaction reports in nine months of 2025

    NGT issues notice to Himachal pharma unit over pollution, water diversion allegations

    NGT issues notice to Himachal pharma unit over pollution, water diversion allegations

    Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns

    Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns

    DGFT Fixes Six New Standard Input Output Norms (SIONs) for Pharmaceutical and Chemical Exports

    DGFT Fixes Six New Standard Input Output Norms (SIONs) for Pharmaceutical and Chemical Exports